report- Acute-Myelocytic-Leukemia-AML-Acute-Myeloblastic-L | Page 7

Dec 01, 2016: argenx to provide update on ARGX-110 during American Society of Hematology Annual Meeting 68 Nov 29, 2016: New Research Validates both Single Agent and Synergistic Anticancer Activity for Aravive Biologics’ Anti-AXL Candidate in Multiple Tumor Types 69 Nov 29, 2016: Actinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical Trials 69 Nov 29, 2016: Astex to Showcase Its Next-Generation Hypomethylating Agent Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology 70 Clinical Trial Profile Snapshots 71 Appendix 1822 Abbreviations 1822 Definitions 1822 Research Methodology 1824 Secondary Research 1825 About GlobalData 1826 Contact Us 1826 Disclaimer 1826 Source 1827 Report Details – Date of Publishing - February 28, 2017 No of Pages – 1827 Single User PDF License – $2500 Corporate License – $7500 Buy Now - https://www.absolutereports.com/purchase/10711136 About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email – [email protected] https://www.absolutereports.com/